## UTHR: United Therapeutics Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.44 indicates fundamental undervaluation. Quality metrics strong (ROE 20%, ROA 13%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($477.58)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Texas Permanent School Fund Corp Increases Holdings in United Therapeutics Corporation $UTHR**
- Source: MarketBeat | 20251215T130907 | Somewhat-Bullish | Relevance: 100%
- Texas Permanent School Fund Corp significantly increased its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 7.2% in the second quarter, valuing its holdings at approximately $14.77 million. This comes despite recent insider selling by executives. Analysts maintain a "Moderate Buy" rating for United Therapeutics with an average price target of $505.00, reflecting confidence in the biotechnology company's performance and future prospects.

**2. Thrivent Financial for Lutherans Has $53.30 Million Holdings in United Therapeutics Corporation $UTHR**
- Source: MarketBeat | 20251215T120907 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans recently reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 9.8%, now holding 185,477 shares valued at $53.30 million. Insider selling has also been noted, with CEO Martine Rothblatt selling shares, though institutional investors still hold a significant portion of the company. United Therapeutics reported Q3 EPS of $7.16, exceeding estimates, and has a "Moderate Buy" consensus rating with a $505 price target.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 16 ($11.29M) |
| Sells | 76 ($45.40M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Blackrock Inc.: 12.4% (+0.4%)
- Vanguard Group Inc: 10.3% (-0.7%)
- Renaissance Technolo: 5.1% (+2.6%)
- Avoro Capital Adviso: 4.7% (-14.7%)
- State Street Corpora: 4.5% (-11.3%)

### Key Risks

1. Heavy insider selling: $45M sold (76 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +6.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.44 suggests fair value with growth premium. Forward P/E 17.6x stretched relative to 5% growth. Quality metrics strong (ROA 13%, margin 41%). Balance sheet: strong liquidity (6.4x), low leverage (D/E 0.12). Insider selling cluster ($45.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.6B |
| Beta | 0.86 |
| 52W Range | $266.98 - $501.05 |
| Short Interest | 5.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.44 |
| Forward P/E | 17.6 |
| Current P/E | 18.5 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -2.1% to 4.0% (+6.1% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 69th percentile. MRS_5 at 3.9% confirms short-term momentum alignment. AM_20 at 3.8% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.00% (CS: 69) | Neutral |
| RSI_14 | 68.7 | Neutral |
| MACD Histogram | -0.03 | Bearish |
| vs SMA20 | 1.038x | Above |
| vs SMA50 | 1.092x | Above |
| vs SMA200 | 1.413x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $500.30
- **Stop Loss:** $477.58 (4.5% risk)
- **Target:** $545.74 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 52
- **Position Value:** $26,015.60
- **Portfolio %:** 26.02%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-25 (Est: $6.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $6.96 | $7.16 | +2.9% |
| 2025Q2 | $6.94 | $6.41 | -7.6% |
| 2025Q1 | $6.28 | $6.63 | +5.6% |
| 2024Q4 | $6.27 | $6.19 | -1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*